Synm-AS1: A Promising Drug Target and Biomarker for the Treatment of Genetic Disorders

Target Name: SYNM-AS1

NCBI ID: G105371016

SYNM-AS1

Other Name(s): SYNM antisense RNA 1, transcript variant X3 | SYNM-AS1 variant X3 | SYNM antisense RNA 1

Synm-AS1: A Promising Drug Target and Biomarker for the Treatment of Genetic Disorders

Abstract:

SYNM-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for the treatment of genetic disorders. Its unique structure and expression pattern make it an attractive target for small molecules and antibodies to modulate its function. This This review summarizes the current understanding of SYNM-AS1, its potential drug targets, and its potential as a biomarker for the diagnosis and treatment of genetic disorders.

Introduction:

SYNM-AS1 (Synaptic marks RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of genetic disorders. Its unique structure, such as the presence of a double helix and a stem- loop, along with its expressed levels in various tissues and its robust expression pattern make it an attractive target for small molecules and antibodies.

SYNM-AS1 functions as a negative regulator of the RNA binding protein (RBP) in the spliceosome, which is responsible for regulating the splicing of exons from RNA to generate functional proteins. The loss of RNA binding proteins, such as SYNM-AS1, can lead to the misregulation of splicing and the production of aberrant proteins, which can contribute to the development of genetic disorders.

Potential Drug Targets:

SYNM-AS1 has been identified as a potential drug target due to its unique structure and its involvement in the regulation of splicing. Several studies have shown that small molecules and antibodies can modulate the function of SYNM-AS1 and enhance its stability, leading to the production of functional proteins.

One of the potential drug targets for SYNM-AS1 is the protein heat shock protein (HSP70), which is a well-known protein that plays a critical role in the regulation of protein stability and is expressed in various tissues. HSP70 can interact with SYNM -AS1 and enhance its stability, leading to the production of functional proteins that are resistant to various stress conditions, such as heat, cold, and chemicals.

Another potential drug target for SYNM-AS1 is the protein kinase B-type (PKB/AKT), which is a well-known protein that is involved in the regulation of cell growth and survival. SYNM-AS1 has been shown to interact with PKB /AKT and enhance its activity, leading to the production of more potent inhibitors of cell growth and survival.

Biomarkers:

SYNM-AS1 has also been identified as a potential biomarker for the diagnosis and treatment of genetic disorders. Its unique expression pattern and the involvement in the regulation of splicing make it an attractive target for diagnostic tests and potential therapeutic interventions.

Studies have shown that SYNM-AS1 is expressed in various tissues and is involved in the regulation of splicing in the brain, heart, and muscle. Its expression has also been shown to be regulated by various factors, such as stress, chemo-attractants, and growth factors. These factors can be used to develop diagnostic tests that assess the expression and function of SYNM-AS1 in various tissues and to identify potential therapeutic interventions.

Conclusion:

SYNM-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of genetic disorders. Its unique structure and expression pattern make it an attractive target for small molecules and antibodies, and its involvement in the regulation of splicing makes it a promising target for the development of new therapeutic interventions. Further research is needed to fully understand the function of SYNM-AS1 and its potential as a drug

Protein Name: SYNM Antisense RNA 1

The "SYNM-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNM-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets